{"id":756319,"date":"2026-06-23T18:04:10","date_gmt":"2026-06-23T18:04:10","guid":{"rendered":"https:\/\/www.newsbeep.com\/ca\/756319\/"},"modified":"2026-06-23T18:04:10","modified_gmt":"2026-06-23T18:04:10","slug":"novartis-canada-and-sp-quebec-celebrate-16-years-of-partnership-through-annual-ms-tri-challenge-fundraiser","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ca\/756319\/","title":{"rendered":"Novartis Canada and SP Quebec Celebrate 16 Years of Partnership Through Annual MS Tri-Challenge Fundraiser"},"content":{"rendered":"<p> The MS Tri-Challenge returns\u00a0to Montreal on Saturday, September 12, 2026, at Parc Jean-Drapeau\u00a0as part of the Sail Challenge Esprit de Montr\u00e9al<\/p>\n<p> Since 2010, Novartis Canada has raised over $650,000 CAD for MS research through the MS Tri-Challenge<\/p>\n<p>MONTREAL, June 23, 2026 \/CNW\/ &#8211; Novartis Pharmaceuticals Canada Inc. (&#8220;Novartis Canada&#8221;) is proud to\u00a0celebrate\u00a016 years of partnership with SP\u00a0Quebec\u00a0through its\u00a0annual fundraising triathlon\u00a0initiative called MS Tri-Challenge.\u00a0For nearly two\u00a0decades, this event\u00a0has brought together\u00a0Novartis\u00a0employees, families, and friends in support of Canadians living with multiple sclerosis (MS)\u00a0in Quebec.\u00a0<\/p>\n<p>Since 2010, participants from the Novartis community have taken part in this unique triathlon, either\u00a0individually or as a team,\u00a0raising more than\u00a0$650,000 CAD\u00a0to advance MS research, support programming, and improve the lives of people affected by the disease.\u00a0<\/p>\n<p>&#8220;Partnerships like the one we share with Novartis Canada are instrumental in driving meaningful projects for research and\u00a0education\u00a0for\u00a0people living with MS\u00a0in Quebec,&#8221; said\u00a0Diego Martinez, Director\u00a0at\u00a0SP\u00a0Quebec. &#8220;The dedication shown year after year by participants reflects a deep commitment to making a tangible difference for the MS\u00a0Qu\u00e9b\u00e9cois\u00a0community.&#8221;\u00a0<\/p>\n<p>The MS Tri-Challenge returns to Montreal\u00a0on Saturday, September 12, 2026, at Parc Jean-Drapeau\u00a0as part of the Sail Challenge Esprit de Montr\u00e9al. Participants can take on a 1.5 km swim, 40 km bike ride, and 10 km run, either individually or as a team. Whether\u00a0you&#8217;re\u00a0a seasoned athlete or simply looking for\u00a0a meaningful\u00a0challenge, everyone is encouraged to\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4717861-1&amp;h=2432076043&amp;u=https%3A%2F%2Fmssp.donordrive.com%2Fevents%2F1381&amp;a=join+this+inspiring+event\" target=\"_blank\" rel=\"nofollow noopener\">join this inspiring event<\/a>\u00a0in support of\u00a0an important\u00a0cause.\u00a0<\/p>\n<p>&#8220;At Novartis, we are committed to reimagining\u00a0MS care,\u00a0not only through innovation, but also through meaningful partnerships that support patients and communities,&#8221; said\u00a0Jason Brown, Vice-President Neuroscience. &#8220;We are incredibly proud of this long-standing collaboration that year after year\u00a0has delivered positive\u00a0impact for Canadians living with multiple sclerosis.&#8221;\u00a0<\/p>\n<p>Canada has one of the highest prevalence rates of multiple sclerosis (MS) globally, with approximately 90,000 individuals affected nationwide, including roughly 20,000 people living with MS in Quebec alone.1,2\u00a0Continued investment in research, advocacy, and patient support\u00a0remains\u00a0critical to addressing the evolving needs of this community.\u00a0<\/p>\n<p>About Multiple Sclerosis <br class=\"dnr\"\/>MS is a chronic, often disabling immune disease that attacks the central nervous system (CNS), made up of the brain, spinal cord, and optic nerve. MS can be characterized into four main types: clinically isolated syndrome (CIS), relapsing remitting (RRMS), secondary progressive (SPMS), and primary progressive (PPMS).2\u202fThese forms can be distinguished based on whether someone experiences relapses (clearly defined acute inflammatory attacks of worsening neurological function), and\/or whether they experience progression of neurologic damage and disability from the onset of the disease.3\u00a0<\/p>\n<p>About\u00a0the Quebec division\u00a0of MS\u00a0Canada <br class=\"dnr\"\/>The Quebec Division of MS Canada\u00a0is the leading source of information, support, and advocacy for people affected by multiple sclerosis (MS) across Quebec. As a regional division of MS Canada, it plays a vital role in connecting individuals living with MS, their families, and caregivers to essential services, resources, and a strong, supportive community.\u00a0<\/p>\n<p>Through a province-wide network of partner organisations and local chapters, the Quebec Division delivers a broad range of programs designed to improve quality of life. These include education and information services, peer support, referrals, wellness tools, and guidance tailored to the needs of people living with MS.\u00a0\u00a0<\/p>\n<p>The organisation is also a strong advocate for the MS community, working to raise public awareness, influence policy, and ensure that the voices of people living with MS are heard in decisions affecting their care and access to services.<\/p>\n<p>About Novartis <br class=\"dnr\"\/>Novartis is an innovative\u00a0medicines\u00a0company. Every day, we work to reimagine medicine to improve and extend people&#8217;s lives so that patients, healthcare\u00a0professionals\u00a0and societies are empowered in the face of serious diseases. Our medicines reach\u00a0nearly 300\u00a0million people worldwide.\u00a0<\/p>\n<p>In Canada,\u00a0Novartis Pharmaceuticals Canada Inc.\u00a0employs approximately\u00a0500\u00a0people\u00a0to serve the evolving needs of patients and the healthcare system and invests over $36 million in R&amp;D yearly in the country.\u00a0Reimagine medicine with us: Visit us at\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4717861-1&amp;h=3567109551&amp;u=https%3A%2F%2Fwww.novartis.ca%2F&amp;a=www.novartis.ca\" target=\"_blank\" rel=\"nofollow noopener\">www.novartis.ca<\/a>\u00a0and connect with us on\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4717861-1&amp;h=3826866501&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fshowcase%2Fnovartis-canada%2F&amp;a=LinkedIn\" target=\"_blank\" rel=\"nofollow noopener\">LinkedIn<\/a>.\u00a0<\/p>\n<p>References<\/p>\n<p> Multiple Sclerosis Canada. (n.d.).\u00a0About MS.\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4717861-1&amp;h=764283951&amp;u=https%3A%2F%2Fmscanada.ca%2Fabout-ms&amp;a=https%3A%2F%2Fmscanada.ca%2Fabout-ms\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/mscanada.ca\/about-ms<\/a>\u00a0\u00a0<br \/>\n Multiple Sclerosis Society of Canada, Quebec Division. (2016).\u00a0Expanding our horizons: Annual report 2016.\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4717861-1&amp;h=511835995&amp;u=https%3A%2F%2Fmscanada.ca%2Fsites%2Fdefault%2Ffiles%2Fdocuments%2F2023-04%2FDivision%2520QC%2520-%2520Annual%2520Report%25202016.pdf%23%3A%7E%3Atext%3DIn%2520Canada%252C%2520we%2520have%2520more%2Care%2520several%2520forms%2520of%2520MS%253A&amp;a=https%3A%2F%2Fmscanada.ca%2Fsites%2Fdefault%2Ffiles%2Fdocuments%2F2023-04%2FDivision%2520QC%2520-%2520Annual%2520Report%25202016.pdf\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/mscanada.ca\/sites\/default\/files\/documents\/2023-04\/Division%20QC%20-%20Annual%20Report%202016.pdf<\/a>\u00a0<br \/>\n MS Society of Canada. (n.d.).\u00a0What is MS: Types.\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4717861-1&amp;h=2814013172&amp;u=https%3A%2F%2Fmssociety.ca%2Fabout-ms%2Ftypes&amp;a=https%3A%2F%2Fmssociety.ca%2Fabout-ms%2Ftypes\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/mssociety.ca\/about-ms\/types<\/a>\u00a0\u00a0<br \/>\n Novartis. (n.d.).\u00a0Types of MS and MS progression.\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4717861-1&amp;h=2033583592&amp;u=https%3A%2F%2Fwww.novartis.com%2Fdiseases%2Fmultiplesclerosis%2Ftypes-ms-and-ms-progression&amp;a=https%3A%2F%2Fwww.novartis.com%2Fdiseases%2Fmultiplesclerosis%2Ftypes-ms-and-ms-progression\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/www.novartis.com\/diseases\/multiplesclerosis\/types-ms-and-ms-progression<\/a>\u00a0\u00a0<\/p>\n<p>SOURCE Novartis Pharmaceuticals Canada Inc.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.newswire.ca\/rt.gif?NewsItemId=C8375&amp;Transmission_Id=202606231300CANADANWCANADAPR_C8375&amp;DateId=20260623\" style=\"border:0px; width:1px; height:1px;\"\/><\/p>\n<p>Novartis\u00a0media contact: Rafaela Righetti, Lead, Communications &amp; Patient Advocacy &#8211; Neuroscience, Phone: 514-633-7873, E-mail:\u00a0<a href=\"https:\/\/www.newswire.ca\/cdn-cgi\/l\/email-protection\" class=\"__cf_email__\" data-cfemail=\"791a1814150911571a1614140c17101a180d1016170a3917160f180b0d100a571a1614\" rel=\"nofollow noopener\" target=\"_blank\">[email\u00a0protected]<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"The MS Tri-Challenge returns\u00a0to Montreal on Saturday, September 12, 2026, at Parc Jean-Drapeau\u00a0as part of the Sail Challenge&hellip;\n","protected":false},"author":2,"featured_media":756320,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[49,48,44,246731],"class_list":["post-756319","post","type-post","status-publish","format-standard","has-post-thumbnail","category-canada","tag-ca","tag-canada","tag-news","tag-novartis-pharmaceuticals-canada-inc"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/756319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/comments?post=756319"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/756319\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media\/756320"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media?parent=756319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/categories?post=756319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/tags?post=756319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}